medigraphic.com
ISSN 1810-2352 (Print)

2013, Number 3

<< Back Next >>

Rev Cub Med Int Emerg 2013; 12 (3)

Characterization of some variables associated with acute myocardial infarction in Tinaco, Cojedes, Republic of Venezuela

Pérez EFA, Balmori MBL, Pérez RE

Language: Spanish
References: 41
Page: 203-214
PDF size: 314.63 Kb.


ABSTRACT

Introduction: In the Bolivarian Republic of Venezuela diseases of hearth and circulation occupy the first place of the death causes in 1999; more than a half were due to myocardial infarction.
Objective: To determine some variables related to morbidity and mortality of the myocardial infarction.
Method: We performed an observational, descriptive, longitudinal, retrospective study using epidemiological methods to evaluate the occurrence of some variables related to morbidity and mortality from acute myocardial infarction (AMI) in the intensive care unit (ICU) of CDI: José Laurencio Silva of Tinaco County, Cojedes State, Bolivarian Republic of Venezuela from January the 1st 2007 until December 31st 2008. The universe of study included all patients discharged from the ICU in the period aforementioned who fulfilled clinical, enzymatic and electrocardiographic criteria considered by the World Health Organization (WHO) for the diagnosis of AMI. A questionnaire was developed to collect all data.
Results: The AMI occurred more frequently in males (72.7%). Killip I functional class was the most common (72.7%). The anterior location was the commonest electrocardiographic finding. Thrombolysis was performed in 44.5% of the patients. The most common side effects during thrombolysis were arrhythmias (80%), tremor and chills (60%) and hypotension (40%). There were no deaths in the group who received thrombolytic therapy.
Conclusions: Patients with thrombolysis exhibited a total reduction of the mortality.


REFERENCES

  1. Fernández Ortiz A. Fisiopatología de la angina inestable. Papel de la rotura y trombosis de la placa aterosclerótica. Rev Esp Cardiol. 1999;52(Supl 1):13-23.

  2. Norris RM. Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group. Br Med J. 1998;316:1.065-70.

  3. Batista IM, Fernández F, Diéguez A, Terrero J. Mortalidad por infarto cardíaco agudo. Indicadores pronósticos. Correo Científico Médico Holguín [Internet]. 2002 [citado 22 Oct 2007]; 6(3): [aprox. 5 p.]. Disponible en: http://www: www.cocmed.sld.cu/no63/n63ori3.html.

  4. MINSAP. Anuario Estadístico de Salud. [Internet] 2007 [citado 22 Oct 2007]. Disponible en: http://www.infomed.sld.cu/servicios/estadisticas

  5. Manrique Leal M, Roy Wong M, Guevara M. Vigilancia epidemiológica para el infarto agudo al miocardio. Acta méd. Costarric [Internet]. 2005 [citado 22 Oct 2007]; 47(2): [aprox. 3 p.]. Disponible en: http://:www.scielo.sa.cr/scielo.php?pid=S0001-60022005000200005&script=sci_arttext

  6. Chávez DR, Ramírez HJ, Casanova GJ La cardiopatía coronaria en México y su importancia clínica, epidemiológica y preventiva. Arch Cardiol Mex. 2003;73(2):105-14.

  7. Bustamante D; Almendarez C. Perfil clínico epidemiológico en pacientes con infarto agudo del miocardio. Rev Méd Hon [Internet]. 2000 [citado 22 Oct 2007];68(1): [aprox. 5 p.]. Disponible en: www.bvs.hn/revmedhon/fulltext/v068_01_2000.pdf

  8. Szot J. Mortalidad por infarto agudo al miocardio en Chile: 1990-2001 Rev Méd Chile. 2004;132:1227-33.

  9. Organización Panamericana de la Salud. Health in the Americas. PAHO [Internet]. 2002 [citado 19 Oct 2005]; 1(587): [aprox. 7 p.]. Disponible en: ISBN 92 75 11587.

  10. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-38.

  11. Udvarhelyi IS, Gatsonis C, Epstein AM. Acute myocardial infarction in the Medicare population. Process of care and clinical outcomes. JAMA. 1992;268:2530-6.

  12. Imazio M, Bobbio M, Bergerone S. Clinical and epidemiological characteristics of juvenile myocardial infarction in Italy: the GISSI experience. G Ital Cardiol. 1998; 28:505-12.

  13. Maggioni AP, Maseri A, Fresco C. On behalf of the Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-2): Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. N Engl J Med. 1993;329:1442-8.

  14. Lee KL, Woodlief LH, Topol EJ. For the GUSTO-1 investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41.021 patients. Circulation. 1995;91:165-8.

  15. Marchioli R, Avanzini F, Barzi F. On behalf of GISSI-Prevenzione Investigators. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations. GISSI-Prevenzione mortality risk chart. Eur Heart J. 2001;22:2085-103.

  16. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet. 2001; 357:1905.

  17. Niveles de estradiol como factor de riesgo de coronariopatías agudas en post-menopáusica[Internet]. Perú; 2003 [citado 10 Dic 2007]. Disponible en: http://www.sisbib.unmsm.edu.pe/BVRevistas/cardiologia/v23_n3/niveles.htm

  18. Fiol M, Cabadés A, Sala J, Marrugat J, Elosua R. Variabilidad en el manejo hospitalario del infarto agudo del miocardio en España. Estudio IBERICA (Investigación Búsqueda Específica y registro de Isquemia Coronaria Aguda). Rev Española Cardiol. 2001;54:443-52.

  19. Cabadés A, Echanove I, Cebrián J, Cardona J, Valls F. Características, manejo y pronóstico del paciente con infarto agudo del miocardio en la comunidad Valencia, en 1995: Resultados del Registro PRIMVAC (Proyecto del Registro de Infarto Agudo del Miocardio de Valencia, Alicante y Castellón). Rev Española Cardiol. 1999 Feb;52(2):123-33.

  20. Cabadés A, Valls F, Echanove I, Francés M, Sanjuán R. Estudio RICVAL. El infarto agudo del miocardio en la ciudad de Valencia. Rev Española Cardiol. 1997 Jun;50(6):383-96

  21. Bosch X, Sambola A, Arós F, López BL, Mancisor X. Utilización de la trombolisis en los pacientes con infarto agudo del miocardio en España: Observaciones del estudio PRIAMHO. Rev Española Cardiol. 2000 Abr;53(4):490-501.

  22. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. INTERHEART study. Lancet. 2004;364:937-52.

  23. Pontet J, Pucurrull L, Méndez H, Pérez M, Betancourt S. Infarto agudo de miocardio. Análisis de cinco años en el CTI del Hospital Pasteur. Paciente crit Uruguay. 2001;14(1):5-26.

  24. Ciruzzi M, Rozlosnik J. Factores de riesgo para infarto de miocardio en la Argentina (FRICAS). Rev Argent Cardiol. 1997;64(Supl II):9-39.

  25. Cabadés A, López-Bescós L, Arós F, Loma-Osorio A, Bosch X, Pabón P, et al. Variabilidad en el manejo y el pronóstico a corto y medio plazo del infarto de miocardio en España: estudio PRIAMHO. Rev Esp Cardiol. 1999;52:767-75.

  26. Goldberg RJ, Gore JM, Thompson CA, Gurwitz JH. Recent magnitude of and temporal trends in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: the second national registry of myocardial infarction. Am Heart J. 2001;141:65-72.

  27. Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja I, et al. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J. 1999;138:1133-9.

  28. Doorey AJ, Michelson EL, Topol EJ. Thrombolytic therapy in acute myocardial infarction. Keeping the unfulfilled promises. JAMA. 1992;268:3.108-14.

  29. Ketley D, Woodss KL. Impact of clinical trials in clinical practice: example of thrombolysis for acute myocardial infarction. Lancet. 1993;342:891-4.

  30. Rouleau L, Talajic M, Sussex B, Potwin L, Warnica W, Davies RF, et al. Myocardial Infarction in 1990s. Their risk factors, stratification and survival in Canada: The Canadian Assesment of Myocardial Infarction (CAMI) Study. J Am Coll Cardiol. 1996;27:1.119-127.

  31. O'Callaghan P, Comerford D, Graham I, Higgins I, Daly L, Robinson W et al. National perspective of acute coronary care in the Republic of Ireland. Br Heart J. 1995;73:576-80

  32. Arós F, Cuñat J, Loma-Osorio A, Torrado E, Bosch X. Tratamiento del infarto agudo de miocardio en España en el año 2000. El estudio PRIAMHO II. Rev esp cardiol. 2003;56(3):1165-73.

  33. Monassier JP, Hannania G, Khalife K, Frelon JH, Boreux C, Fournier P. Strategies therapeutiques a la phase aigue de l`infarctus du myocarde. Résultats du registre STIM. Arch Mal Coeur. 1996;89:281-9.

  34. The GUSTO Investigators. An International randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-82.

  35. Comité de Cardiopatía Isquémica de la Federación Argentina de Cardiología. Registro Nacional de Infarto Agudo al Miocardio de la Federación Argentina de Cardiología. Rev Fed Arg Cardiol. 2004;33:127-31.

  36. National Heart Attack Alert Program Coordinating Committee, 60 minutes to Treatment Working Group. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med. 1994;23: 311-29.

  37. Iglesias ML, Pedrot – Botet J, Hernández E, Sulsona JF. Tratamiento fibrinolítico en el infarto agudo del miocardio: análisis de los tiempos de demora. Rev Med Clín Esp. 1998;106(8):281-7.

  38. Latour J, López Camps V, Rodríguez Serra M, Giner JS, Bonastre J, Rosado L. Pronostico del infarto agudo de miocardio en mujeres. Efecto del esfuerzo terapéutico y del nivel socioeconómico. Rev Esp Cardiol. 1992;45:560-5.

  39. Corbalán R, Nazzal C, Prieto J, Chávez E, Lanas F, Lamich R, et al. Reducción de la mortalidad por infarto del miocardio en hospitales chilenos. Rev Méd Chile. 2002; 130:368-78.

  40. Gurwitz JH, Gore JM, Golberg RJ. Recent age-related trends in the use of thrombolytic therapy in patients who have had myocardial infarction. Ann Intern Med. 1996;124:283-91.

  41. Fibrinolytic Therapy Trialists Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311-22.




2020     |     www.medigraphic.com